Biosite Research is one of India’s leading mid-sized CROs in late-stage research. They work with pharmaceutical companies and patients across India and have recently expanded to the UK. The company has over 100 years of collective expertise in designing, conducting and translating complex clinical studies, from writing scientific protocols to submitting reports to CDSCO. They offer end-to-end personalized research services to meet the research and development and production needs of their clients with the highest standards of ethics and good clinical practice.
Dr. Aditi Datta is the founder and CEO of Biosite Research. She oversees the development and implementation of Biosite’s scientific and strategic direction. She helps provide the direction needed to drive his growth and achieve his goal of becoming the CRO of choice. In an exclusive interview, she tells us more about the company. Excerpts from an interview:
Q. Tell us about your company Biosite Research and the services it offers?
Biosite Research started in 2015 in a room in Saket City Hospital (now Max hospital Saket, New Delhi). At that time, I was responsible for conducting a USFDA clinical research study for Teva. After we successfully completed the study with the USFDA audit approval, we expanded our services to several hospitals, including government hospitals, and built up a large team offering research services to various departments of these hospitals. We have established a security framework, quality record and compliance. We have developed a strong supply chain and access to qualified scientists. Our approach has allowed us to build client relationships that have extended beyond the standard service delivery model to become truly lasting partnerships.
We moved our head office to Bangalore. Initially, building the company was challenging, but in 2017, we hired talented people who ran end-to-end clinical trials for select pharmaceutical companies and biotech organizations. We started the business to provide quality services at affordable prices. We believe that better clinical research services must be performed to give accurate results for drugs that are in the development phase before marketing authorization. Today, the company has transformed into a multinational and carries out projects worth 50 crores.
Q. How is your business different from your competitors?
As one of India’s leading mid-sized clinical CROs, Biosite has extensive regional experience and infrastructure to conduct its clients’ clinical trials. We guide our clients from clinical development planning to regulatory filing and approvals. We provide flexible solutions and ensure that budget and deadlines are met, reducing risk and client delays. We have therapeutic expertise and scientific experts who ensure that the quality of services is not compromised.
Our team’s collaborative approach helps us understand the specific resource needs of our clients, and then we provide a talented and experienced team for the program. We also provide collaborative technologies that help our customers make informed decisions.
We also focus on team building and a friendly atmosphere for employees. We have a dedicated team that is committed to meeting targets and working overtime.
Q. What were the challenges the business faced during the pandemic and how did you overcome them?
During the pandemic, it was difficult for a medium-sized company like ours to sustain itself, but our courage and determination kept us going. Due to previous work experience, we have started receiving Covid-19 projects. We were skeptical about taking such a huge risk, but we took the risk anyway. As it was a new and unknown disease, we did not know the consequences. We have maintained care and protection. Our team was on the ground in hospitals researching covid and trying to find the best possible cure for this deadly disease. We did an end-to-end study on the use of IVIG for patients with Covid-19.
Q. What is your business goal and how do you plan to achieve it? Do you have any other long term goals?
Our goal is to set a benchmark for clinical research standards and provide the best services to all of our customers in countries like the US, UK and other European regions. Our goal is to increase business opportunities for the Indian clinical trials industry.
Regarding long-term goals, we have already launched a biotechnology company that will offer its own biosimilar products and medical devices based on innovative technology.
Q. What new technologies are you using in your business?
The best way to execute a project quickly is to introduce technology. We use Electronic Case Report Form (ECRF) platforms, where data is captured and can be further analyzed by statisticians and data analysts. eTMF is another interesting platform that replaces the conventional TMF. We use these technologies to stay ahead of our competitors.
Q. What do you see when you hire talent in your organization? How big is your team ?
When hiring a new employee, we look at their attitude and integrity towards work. We believe that a person with a positive attitude can easily fit into the culture and achieve the desired goals for the organization. We believe that anyone who is passionate about learning new things can grow with the company. In addition, we also examine its expertise in the field.
In terms of team size, we have a core team of 25 people ranging from medical fraternity and KOL scientific experts guiding on different clinical trial indications to project managers, quality assurance analysts and data and PHD researchers, statisticians who work together to run the project. We also have CRAs and experts who work on a project basis. Overall, the team is scalable to 50 -100 depending on project requirements.
Q. What inspires you?
I draw inspiration from people working in the scientific community who have come a long way, especially women entrepreneurs such as Ms. Kiran Mazumdar Shaw, President of Biocon Group.
On a personal level, I would say that the parents played an exceptional role in bringing out the best in me. My mother has always supported me. She always advised me to choose my own path instead of following in the footsteps of others.
Q. What is the best advice you can give our readers?
The only way to succeed in life is to never give up on your dreams. Be consistent and passionate about your work, the sky is the limit.
Articles under “Fortune India Exchange” are either infomercials or advertisements. Fortune India’s editorial staff or reporters are not involved in the writing or production of these articles.